Proton MR spectroscopy in clinical routine

In vivo magnetic resonance spectroscopy (MRS) addresses metabolic pathways and their steady states in different tissue types. The brain has by tradition, and due to technical limitations in other organs, been one of the tissues most studied by MRS, and both 1H‐ and 31P‐MRS have been used. Although 31P‐MRS is outstanding for the evaluation of sources of metabolic energy in the brain, 1H‐MRS has become the major clinically applied method in neurospectroscopy, as it provides information on markers of neuronal function, myelin, cell membranes, and metabolic active compounds. Furthermore, MR sensitivity is much greater for protons than it is for phosphorus and 1H‐MRS, therefore allowing better spatial resolution. This review focuses on neurospectroscopy and diagnostic insights into diverse neurological problems provided by 1H‐MRS applied as a clinical tool. J. Magn. Reson. Imaging 2001;13:560–567. © 2001 Wiley‐Liss, Inc.

[1]  D. Arnold,et al.  Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. , 1999, Archives of neurology.

[2]  R. Kreis,et al.  Hypoxic encephalopathy after near-drowning studied by quantitative 1H-magnetic resonance spectroscopy. , 1996, The Journal of clinical investigation.

[3]  D. Arnold,et al.  Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images , 1994, Annals of neurology.

[4]  K. Laxer Clinical Applications of Magnetic Resonance Spectroscopy , 1997, Epilepsia.

[5]  P R Luyten,et al.  Observation of metabolites in the human brain by MR spectroscopy. , 1986, Radiology.

[6]  A R Tate,et al.  Towards a method for automated classification of 1H MRS spectra from brain tumours , 1998, NMR in biomedicine.

[7]  D. Gadian,et al.  Magnetic resonance spectroscopy in temporal lobe epilepsy , 1994, Neurology.

[8]  D Shedid,et al.  MRS Metabolic Markers of Seizures and Seizure‐Induced Neuronal Damage , 1998, Epilepsia.

[9]  P M Pattany,et al.  MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. , 2000, AJNR. American journal of neuroradiology.

[10]  L. Kappelle,et al.  Cerebral metabolic changes in patients with a symptomatic occlusion of the internal carotid artery: A longitudinal 1H magnetic resonance spectroscopy study , 2000, Journal of magnetic resonance imaging : JMRI.

[11]  U. Klose,et al.  Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy. , 1991, Radiology.

[12]  E. Achten,et al.  Value of single-voxel proton MR spectroscopy in temporal lobe epilepsy. , 1997, AJNR. American journal of neuroradiology.

[13]  E. Laws Imaging brain tumors — beyond three dimensions , 1996, Nature Medicine.

[14]  A R Tate,et al.  Lipid metabolite peaks in pattern recognition analysis of tumour in vivo MR spectra. , 1996, Anticancer research.

[15]  M. Weiner,et al.  Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging. , 2000, Radiology.

[16]  Matthijs Oudkerk,et al.  1H MR Spectroscopy Detection of Lipids and Lactate in Metastatic Brain Tumors , 1996, NMR in biomedicine.

[17]  Brian D. Ross,et al.  Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases , 1999 .

[18]  D. Arnold,et al.  Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors , 1998, NMR in biomedicine.

[19]  J Hennig,et al.  Grading and therapy monitoring of astrocytomas with 1H-spectroscopy: preliminary study. , 1996, Anticancer research.

[20]  R. Kuzniecky,et al.  Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging , 1996, Annals of neurology.

[21]  D. Gadian,et al.  H magnetic resonance spectroscopy in the investigation of intractable epilepsy , 1994, Acta neurologica Scandinavica. Supplementum.

[22]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[23]  C. Arús,et al.  Diagnosis of Brain Abscess by Magnetic Resonance Spectroscopy. Report of Two Cases , 1997 .

[24]  B J Soher,et al.  Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference , 1993, NMR in biomedicine.

[25]  D. Louis Collins,et al.  Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy , 1996, Nature Medicine.

[26]  H Soltanian-Zadeh,et al.  Brain tumor segmentation and characterization by pattern analysis of multispectral NMR images , 1998, NMR in biomedicine.

[27]  M. Castillo,et al.  Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. , 1998, Magnetic resonance imaging clinics of North America.

[28]  J. McConnell,et al.  Proton spectroscopy of brain glutamine in acute liver failure , 1995, Hepatology.

[29]  D. Arnold Magnetic resonance spectroscopy: imaging axonal damage in MS , 1999, Journal of Neuroimmunology.

[30]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[31]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[32]  B. Ross,et al.  The biochemistry of living tissues: Examination by MRS , 1992, NMR in biomedicine.

[33]  J. D. de Certaines,et al.  Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. , 1996, Anticancer research.

[34]  P M Matthews,et al.  Correlating magnetic resonance imaging markers of axonal injury and demyelination in motor impairment secondary to stroke and multiple sclerosis. , 2000, Magnetic resonance imaging.

[35]  Roland Kreis,et al.  Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy , 1993, Magnetic resonance in medicine.

[36]  K. McCully,et al.  Nuclear magnetic resonance spectroscopy: its role in providing valuable insight into diverse clinical problems. , 1999, Chest.

[37]  D M Doddrell,et al.  A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. , 1999, Magnetic resonance imaging.

[38]  New NMR measurements in epilepsy. T2 relaxometry and magnetic resonance spectroscopy. , 1999, Advances in neurology.

[39]  F Ståhlberg,et al.  Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. , 2000, AJNR. American journal of neuroradiology.

[40]  R L Somorjai,et al.  Near‐optimal region selection for feature space reduction: novel preprocessing methods for classifying MR spectra , 1998, NMR in biomedicine.

[41]  J Kurhanewicz,et al.  The prostate: MR imaging and spectroscopy. Present and future. , 2000 .

[42]  F. Podo,et al.  Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. , 1996, Anticancer research.

[43]  M. Castillo,et al.  Clinical applications of proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[44]  J. Frahm,et al.  Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.

[45]  P. M. Matthews,et al.  Short‐term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders , 1995, Neurology.

[46]  K. Hara,et al.  Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[47]  Mark Noble,et al.  Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours , 1995, NMR in biomedicine.

[48]  D. Arnold,et al.  In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging , 1998, Annals of neurology.

[49]  loannis Constantinidis MAGNETIC RESONANCE SPECTROSCOPY AND THE PRACTICING NEUROLOGIST , 1998 .

[50]  N. Makris,et al.  An Integrated Strategy for Evaluation of Metabolic and Oxidative Defects in Neurodegenerative Illness Using Magnetic Resonance Techniques , 1999, Annals of the New York Academy of Sciences.

[51]  J. Langston,et al.  Proton MR spectroscopy of pediatric brain tumors. , 1998, Neuroimaging clinics of North America.

[52]  N. Lundbom,et al.  Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. , 1997, Journal of Neurosurgery.

[53]  G. Hagberg,et al.  From magnetic resonance spectroscopy to classification of tumors. A review of pattern recognition methods , 1998, NMR in biomedicine.

[54]  S. Holtås,et al.  In vivo proton MR spectroscopy of untreated and treated brain abscesses. , 1999, AJNR. American journal of neuroradiology.

[55]  Der,et al.  Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain. , 1990, Radiology.

[56]  A. R. Tate,et al.  Pattern recognition analysis , 1998 .

[57]  C Morriss,et al.  Prediction of posterior fossa tumor type in children by means of magnetic resonance image properties, spectroscopy, and neural networks. , 1997, Journal of neurosurgery.

[58]  J Hennig,et al.  Human brain tumors: assessment with in vivo proton MR spectroscopy. , 1993, Radiology.

[59]  M. Castillo,et al.  Proton MR spectroscopy of common brain tumors. , 1998, Neuroimaging clinics of North America.